Info@ThinkPinkRocks.com

Allergan, Rugen Therapeutics collaborate to discover and develop novel therapies for ASD and OCD

Allergan plc, a leading global pharmaceutical company, and Rugen Therapeutics, a start-up biotechnology company focused on the development of novel treatments for unmet CNS disorders and funded by the F-Prime Biomedical Research Initiative, today announced that they have entered into an exclusive collaboration to support the discovery and development of novel therapies for Autism Spectrum Disorders (ASD) and Obsessive Compulsive disorders (OCD).

More:
Allergan, Rugen Therapeutics collaborate to discover and develop novel therapies for ASD and OCD

Share

Leave a Reply